Navarria et al 76 (118) Prospective CS High 1–5 lung metastases, controlled Overall, Not used (2014) primary tumour, no progressive PF 18 (6–45) months disease longer than 6 months, survival, adverse medically inoperable events Navarria et al 28 (51) Prospective CS High 1–4 lung metastases, Overall survival, Not used (2015) disease, controlled adverse events 21 (8–20) months primary tumour, progressive disease after chemo ± surgery Norihasa et al 34 (43) Retrospective CS High 1–2 pulmonary metastases, ≤ 40 Overall, Not used (2008) mm, locally controlled primary survival, 27 (10–80) tumour, no other metastatic sites adverse events months Nuyttens et al 30 (57) Prospective CS High 1–5 lung metastases, inoperable Overall, Not used (2015) or refused surgery, primary under survival, 36 (4–60) months control adverse events Oh et al 57 (67) Retrospective CS High 1–4 lung metastases, < 50 mm, Overall survival, Not used (2012) with a controlled primary tumour adverse events 21 (3–107) months Osti et al 66 (103) Prospective CS High 1–2 lung metastases, < 50 mm, Overall, Not used (2013) controlled extra thoracic disease PF 15 (3–45) months survival, adverse events Ricardi et al 61 (77) Retrospective CS High Patients with 1–3 lung Overall, Not used (2011) metastases, <50mm, absent or PF 20 (3–77) months controlled extra thoracic disease survival, adverse events Takahashi et 34 (44) Retrospective CS High Colorectal lung metastases, Overall survival, Not used al (2014) resected primary, inoperable, no adverse events 24 (6–167) other metastases months Meta-analysis/ 808 Where possible n/N (%) for Not used pooling adverse events has been 17 studies calculated across all studies. Measures of central tendency and associated measures of variance have been reported if applicable < CS = case series; IQR = interquartile range; mm = millimetres; n/N (%) = number with event/ total (percentage); NR = not reported; PF = progression-free >
Navarria et al (2014) 76 (118) Prospective CS 18 (6–45) months High 1–5 lung metastases, controlled primary tumour, no progressive disease longer than 6 months, medically inoperable Overall, PF survival, adverse events Not used Navarria et al (2015) 28 (51) Prospective CS 21 (8–20) months High 1–4 lung metastases, disease, controlled primary tumour, progressive disease after chemo ± surgery Overall survival, adverse events Not used Norihasa et al (2008) 34 (43) Retrospective CS 27 (10–80) months High 1–2 pulmonary metastases, ≤ 40 mm, locally controlled primary tumour, no other metastatic sites Overall, survival, adverse events Not used Nuyttens et al (2015) 30 (57) Prospective CS 36 (4–60) months High 1–5 lung metastases, inoperable or refused surgery, primary under control Overall, survival, adverse events Not used Oh et al (2012) 57 (67) Retrospective CS 21 (3–107) months High 1–4 lung metastases, < 50 mm, with a controlled primary tumour Overall survival, adverse events Not used Osti et al (2013) 66 (103) Prospective CS 15 (3–45) months High 1–2 lung metastases, < 50 mm, controlled extra thoracic disease Overall, PF survival, adverse events Not used Ricardi et al (2011) 61 (77) Retrospective CS 20 (3–77) months High Patients with 1–3 lung metastases, <50mm, absent or controlled extra thoracic disease Overall, PF survival, adverse events Not used Takahashi et al (2014) 34 (44) Retrospective CS 24 (6–167) months High Colorectal lung metastases, resected primary, inoperable, no other metastases Overall survival, adverse events Not used Meta-analysis/ pooling 808 17 studies Where possible n/N (%) for adverse events has been calculated across all studies. Measures of central tendency and associated measures of variance have been reported if applicable Not used < CS = case series; IQR = interquartile range; mm = millimetres; n/N (%) = number with event/ total (percentage); NR = not reported; PF = progression-free >
1403%20-%20Final%20Contracted%20Assessment%20Report%20(ACCESSIBLE).docx